Julian Baker’s Syndax Pharmaceuticals SNDX Stock Holding History

Julian Baker’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-110,729	Closed	-$2.66M	–	120
2022 Q3	$2.66M	Hold	110,729	–	–	0.02%	96
2022 Q2	$2.13M	Hold	110,729	–	–	0.01%	97
2022 Q1	$1.92M	Hold	110,729	–	–	0.01%	102
2021 Q4	$2.42M	Hold	110,729	–	–	0.01%	105
2021 Q3	$2.12M	Buy	+110,729	New	+$1.85M	0.01%	110

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Julian Baker's SNDX Position: Q4 2022 in Review

Julian Baker sold out of Syndax Pharmaceuticals (SNDX) in Q4 2022, closing a stake of 110,729 shares — an estimated $2.66M sold.

Julian Baker first reported a position in SNDX in Q3 2021 and held it in 5 quarters. The position peaked at $2.66M in Q3 2022. 160 funds tracked by Wall St. Rank hold SNDX as of Q4 2022.

Julian Baker reported no remaining Syndax Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Julian Baker sold 110,729 Syndax Pharmaceuticals shares in Q4 2022, an estimated $2.66M.
Julian Baker first reported a position in Syndax Pharmaceuticals in Q3 2021 and held it in 5 quarters.
Julian Baker's Syndax Pharmaceuticals position peaked at $2.66M in Q3 2022.
160 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2022.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.